Cardiology research and market perseveres through Covid-19 pandemic

On 9 March, the American College of Cardiology (ACC) cancelled its 2020 Scientific Session and moved the event to a three-day virtual experience. Despite the ongoing Covid-19 pandemic, there are ongoing efforts to minimise the outbreak’s impact on advancements in cardiology research and the management of cardiovascular diseases in order to aid front-line physicians continuing to treat these patients.

Elective and non-emergent surgical procedures have been recommended to be minimised, postponed, or cancelled. However, select cardiovascular surgical procedures remain essential, such as urgent percutaneous coronary intervention and heart valve procedures. Prior to the outbreak of Covid-19, GlobalData estimated that these markets would grow at a Compound Annual Growth Rate (CAGR) of approximately 5% over the next ten years. While many markets across the medtech industry will experience an impact to growth due to the pandemic, GlobalData expects that the cardiology market as a whole may experience less of an impact compared to others. Continuing care for patients with cardiovascular diseases remains critical, especially due to their increased risk to Covid-19 and the urgent nature of their treatments.

The ACC’s 2020 Scientific Session will provide the latest knowledge in treatments and results from major clinical trials in all areas of cardiology, including heart failure, acute and stable ischemic heart disease, valvular heart disease, congenital heart disease, and arrhythmias. The continuation of this exchange of knowledge continues to support front-line physicians providing cardiovascular care, as well as the growth of the cardiology market as a whole.